Antivascular endothelial growth factor agents and their development: Therapeutic implications in ocular diseases

被引：105
作者：
Kaiser, Peter K. [1 ]
机构：
[1] Cleveland Clin, Cleveland, OH 44106 USA
来源：
AMERICAN JOURNAL OF OPHTHALMOLOGY | 2006年 / 142卷 / 04期
关键词：
COHERENCE TOMOGRAPHY FINDINGS; VASCULAR-PERMEABILITY FACTOR; INTRAVITREAL INJECTION; TUMOR-CELLS; BEVACIZUMAB AVASTIN(R); MACULAR DEGENERATION; VEGF; RECEPTOR; NEOVASCULARIZATION; ANTIBODY;
D O I：
10.1016/j.ajo.2006.05.061
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
PURPOSE: To provide an overview of angiogenesis and vascular endothelial growth factor (VEGF) and discusses the development approach, safety, and efficacy results of current and emerging anti-VEGF therapies for ocular diseases. DESIGN: Analysis of literature and current clinical trials of antiangiogenic agents for age-related macular degeneration (AMD). METHODS: Literature review. RESULTS: There are several novel antiangiogenic molecules that target vascular endothelial growth factor and are being used in the management of AMD. Large scale, Phase III trials have shown promising results in improving vision in this devastating disease. CONCLUSIONS: Therapies that target VEGF have shown tremendous promise as treatments for AMD.
引用
收藏
页码：660 / 668
页数：9
相关论文
共 56 条
[1]   VASCULAR ENDOTHELIAL GROWTH-FACTOR IN OCULAR FLUID OF PATIENTS WITH DIABETIC-RETINOPATHY AND OTHER RETINAL DISORDERS [J].
AIELLO, LP ;
AVERY, RL ;
ARRIGG, PG ;
KEYT, BA ;
JAMPEL, HD ;
SHAH, ST ;
PASQUALE, LR ;
THIEME, H ;
IWAMOTO, MA ;
PARK, JE ;
NGUYEN, HV ;
AIELLO, LM ;
FERRARA, N ;
KING, GL .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (22) :1480-1487
[2]   Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal [J].
Benjamin, LE ;
Golijanin, D ;
Itin, A ;
Pode, D ;
Keshet, E .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (02) :159-165
[3]   Selection and analysis of an optimized anti-VEGF antibody: Crystal structure of an affinity-matured Fab in complex with antigen [J].
Chen, Y ;
Wiesmann, C ;
Fuh, G ;
Li, B ;
Christinger, HW ;
McKay, P ;
de Vos, AM ;
Lowman, HB .
JOURNAL OF MOLECULAR BIOLOGY, 1999, 293 (04) :865-881
[4]   Cytokine traps: multi-component, high-affinity blockers of cytokine action [J].
Economides, AN ;
Carpenter, LR ;
Rudge, JS ;
Wong, V ;
Koehler-Stec, EM ;
Hartnett, C ;
Pyles, EA ;
Xu, XB ;
Daly, TJ ;
Young, MR ;
Fandl, JP ;
Lee, F ;
Carver, S ;
McNnay, J ;
Bailey, K ;
Ramakanth, S ;
Hutabarat, R ;
Huang, TT ;
Radziejewski, C ;
Yancopoulos, GD ;
Stahl, N .
NATURE MEDICINE, 2003, 9 (01) :47-52
[5]   Vascular endothelial growth factor is essential for corpus luteum angiogenesis [J].
Ferrara, N ;
Chen, H ;
Davis-Smyth, T ;
Gerber, HP ;
Nguyen, TN ;
Peers, D ;
Chisholm, V ;
Hillan, KJ ;
Schwall, RH .
NATURE MEDICINE, 1998, 4 (03) :336-340
[6]   Vascular endothelial growth factor: Basic science and clinical progress [J].
Ferrara, N .
ENDOCRINE REVIEWS, 2004, 25 (04) :581-611
[7]   PITUITARY FOLLICULAR CELLS SECRETE A NOVEL HEPARIN-BINDING GROWTH-FACTOR SPECIFIC FOR VASCULAR ENDOTHELIAL-CELLS [J].
FERRARA, N ;
HENZEL, WJ .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 161 (02) :851-858
[8]   Role of vascular endothelial growth factor in Physiologic and Pathologic angiogenesis: Therapeutic implications [J].
Ferrara, N .
SEMINARS IN ONCOLOGY, 2002, 29 (06) :10-14
[9]   Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene [J].
Ferrara, N ;
CarverMoore, K ;
Chen, H ;
Dowd, M ;
Lu, L ;
OShea, KS ;
PowellBraxton, L ;
Hillan, KJ ;
Moore, MW .
NATURE, 1996, 380 (6573) :439-442
[10]   Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration [J].
Gaudreault, J ;
Fei, D ;
Rusit, J ;
Suboc, P ;
Shiu, V .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2005, 46 (02) :726-733
123456